STOCK TITAN
  1. Home
  2. Sec-filings
  3. SOPH
  4. [Form 4] SOPHiA GENETICS SA Insider Trading Activity

President of SOPHiA GENETICS (SOPH) awarded RSUs and stock options

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

SOPHiA GENETICS SA granted President Ross Muken equity-based compensation on April 2, 2026. He received options to buy 628,743 ordinary shares at $5.04 per share, exercisable until April 2, 2036, and 431,211 restricted stock units that convert into ordinary shares as they vest.

According to the vesting terms, 25% of the RSUs vest on April 2, 2027, with the remaining 75% vesting in equal quarterly installments through April 2, 2030. The share options vest 25% on April 2, 2027, then in equal monthly installments through April 2, 2030, contingent on continued service.

Positive

  • None.

Negative

  • None.
Insider Muken Ross
Role President
Type Security Shares Price Value
Grant/Award Share Option (Right to Buy) 628,743 $0.00 --
Grant/Award Ordinary Shares 431,211 $0.00 --
Holdings After Transaction: Share Option (Right to Buy) — 628,743 shares (Direct); Ordinary Shares — 431,211 shares (Direct)
Footnotes (1)
  1. Represents a restricted stock unit ("RSU") grant made under the Issuer's 2021 Equity Incentive Plan. Each RSU represents a contingent right to receive one ordinary share of the Issuer, subject to the Reporting Person's continued service with the Issuer through each applicable vesting date. 25% of the RSUs will vest on April 2, 2027, and the remaining 75% will vest in equal quarterly installments through April 2, 2030. The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2027, and then in equal monthly installments through April 2, 2030.
Stock options granted 628,743 options Granted April 2, 2026 to President Ross Muken
Option exercise price $5.04 per share Exercise price for 628,743 options expiring April 2, 2036
RSUs granted 431,211 RSUs Awarded under 2021 Equity Incentive Plan on April 2, 2026
RSU vesting start 25% on April 2, 2027 Initial vesting tranche for RSU grant
RSU remaining vesting 75% through April 2, 2030 Vests in equal quarterly installments
Option vesting 25% on April 2, 2027 Remainder vests in equal monthly installments to April 2, 2030
Option expiration April 2, 2036 Expiration date for 628,743 share options
restricted stock unit ("RSU") financial
"Represents a restricted stock unit ("RSU") grant made under the Issuer's 2021 Equity Incentive Plan."
2021 Equity Incentive Plan financial
"Represents a restricted stock unit ("RSU") grant made under the Issuer's 2021 Equity Incentive Plan."
vesting financial
"25% of the RSUs will vest on April 2, 2027, and the remaining 75% will vest in equal quarterly installments"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
share option financial
"The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2027"
exercise price financial
"conversion_or_exercise_price": "5.0400""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Muken Ross
(Last)(First)(Middle)
C/O SOPHIA GENETICS INC.
401 PARK DRIVE, FLOOR 5
(Street)
BOSTON MASSACHUSETTS 02215
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
SOPHiA GENETICS SA [ SOPH ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
President
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/02/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Ordinary Shares04/02/2026A431,211(1)A$0431,211D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Share Option (Right to Buy)$5.0404/02/2026A628,743 (2)04/02/2036Ordinary Shares628,743$0628,743D
Explanation of Responses:
1. Represents a restricted stock unit ("RSU") grant made under the Issuer's 2021 Equity Incentive Plan. Each RSU represents a contingent right to receive one ordinary share of the Issuer, subject to the Reporting Person's continued service with the Issuer through each applicable vesting date. 25% of the RSUs will vest on April 2, 2027, and the remaining 75% will vest in equal quarterly installments through April 2, 2030.
2. The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2027, and then in equal monthly installments through April 2, 2030.
Remarks:
/s/ Elimara Brunetto as Attorney-in-fact for Ross Muken04/03/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did SOPHiA GENETICS (SOPH) report for Ross Muken?

SOPHiA GENETICS reported equity grants to President Ross Muken. He received options on 628,743 ordinary shares at $5.04 per share and 431,211 restricted stock units, all as compensation awards subject to vesting and continued service with the company over several years.

How many RSUs were granted to SOPHiA GENETICS President Ross Muken?

Ross Muken was granted 431,211 restricted stock units. Each RSU represents a contingent right to receive one ordinary share, with 25% vesting on April 2, 2027 and the remaining 75% vesting in equal quarterly installments through April 2, 2030, assuming continued service.

What are the terms of the stock options granted to Ross Muken at SOPHiA GENETICS?

Ross Muken received options on 628,743 ordinary shares at an exercise price of $5.04 per share. The options vest 25% on April 2, 2027, then in equal monthly installments through April 2, 2030, and expire on April 2, 2036, conditioned on continued service.

When do Ross Muken’s RSUs at SOPHiA GENETICS vest?

His RSUs vest over roughly three years. 25% of the 431,211 RSUs vest on April 2, 2027, while the remaining 75% vest in equal quarterly installments through April 2, 2030, provided he continues to serve at SOPHiA GENETICS during the vesting period.

Are Ross Muken’s equity awards at SOPHiA GENETICS open-market purchases?

No, these are compensation grants, not open-market purchases. The Form 4 shows awards of stock options and restricted stock units at a price of $0.00 per share, reflecting grants under the company’s 2021 Equity Incentive Plan rather than buys on the public market.

What plan governs the RSU grant to Ross Muken at SOPHiA GENETICS?

The RSU grant to Ross Muken was made under SOPHiA GENETICS’ 2021 Equity Incentive Plan. Each RSU represents a contingent right to receive one ordinary share, subject to vesting conditions and his continued service with the company through the specified vesting dates.